ReviewFrontiers in microbiology2026
Low-power NIR-mediated photothermal and photodynamic therapy as a synergistic strategy against superbugs.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance is overburdening the health crisis around the globe. Misuse or overuse of antibiotics is one of the reasons for this issue. Therefore, it urges an alternative treatment strategy that can overcome the issue of bacteria being resistant. Photothermal and photodynamic therapies are emerging strategies, being an antibiotic-free solution to treat infections. This method utilizes antimicrobial treatment with heat and ROS, which makes it challenging for bacteria to become resistant. Earlier photothermal therapies required high-power laser sources, which had a significant risk of damaging healthy tissues in the vicinity. Recent research has shown that low-power NIR sources have great potential to achieve equivalent photothermal conversion efficiency when used with different sets of engineered photothermal agents and are also safe for use. A synergistic, low-power antimicrobial strategy combining the photodynamic properties and photothermal properties of the materials results in better efficiency. Additionally, leveraging the NIR-II range allows for deeper penetration into tissues, making it effective to treat deep-seated infections. This review highlights recent advancements in low-power NIR mediated PTT/PDT for mitigating drug-resistant bacteria, focusing on mechanisms, therapeutic outcomes, challenges, and future prospects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.